Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2008 Aug 1;48(4):485-90.
doi: 10.1097/QAI.0b013e31817dc42b.

Effect of HAART on incident cancer and noncancer AIDS events among male HIV seroconverters

Meredith S Shiels  1 , Stephen R Cole, Scott Wegner, Haroutune Armenian, Joan S Chmiel, Anuradha Ganesan, Vincent C Marconi, Otoniel Martinez-Maza, Jeremy Martinson, Amy Weintrob, Lisa P Jacobson, Nancy F Crum-Cianflone
Affiliations
Multicenter Study

Effect of HAART on incident cancer and noncancer AIDS events among male HIV seroconverters

Meredith S Shiels et al. J Acquir Immune Defic Syndr. .

Abstract

Objective: To explore the impact of highly active antiretroviral therapy (HAART) on the prevention of AIDS-defining cancers relative to other AIDS-defining events.

Design: Prospective cohort study using 2,121 HIV+ male seroconverters (median age: 28 years, 51% white/non-Hispanic) in the Tri-Service AIDS Clinical Consortium (n = 1694) and the Multicenter AIDS Cohort Study (n = 427).

Methods: Poisson regression models, with calendar periods to represent antiretroviral therapy, were extended to analyze first incident AIDS-defining cancers and other first AIDS-defining events as competing risks.

Results: Eighty-one AIDS-defining cancers (64 Kaposi sarcomas; 17 non-Hodgkin lymphomas) and 343 other AIDS events occurred during 14,483 person-years in 1990-2006. The rate ratio of AIDS-defining cancers during the HAART calendar period was 0.26 (95% confidence limits: 0.15, 0.46) and of other AIDS-defining events was 0.28 (95% confidence limits: 0.21, 0.36) compared with the monotherapy/combination therapy calendar period, adjusting for age, infection duration, race, and cohort. The association of HAART with decreased AIDS incidence seemed to be equal (interaction ratio = 0.95 (95% confidence limits: 0.51, 1.74) for AIDS-defining cancers and other AIDS-defining events.

Conclusions: In human immunodeficiency virus-infected men, HAART seems equally protective against first AIDS-defining cancers and other first AIDS-defining events.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Antiretroviral therapy use by calendar year among participants in the Tri-service AIDS Clinical Consortium and the Multicenter AIDS Cohort Study, 1987-2006.
See this image and copyright information in PMC

References

    1. Cameron DW, Heath-Chiozzi M, Danner S, et al. The Advanced HIV Disease Ritonavir Study Group Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet. 1998;351(9102):543–549. - PubMed
    1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337(11):725–733. - PubMed
    1. Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA. 1998;280(17):1497–1503. - PubMed
    1. Palella FJ, Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338(13):853–860. - PubMed
    1. Cole SR, Hernan MA, Robins JM, et al. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol. 2003;158(7):687–694. - PubMed

Publication types

MeSH terms

Substances